Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists
Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.
1. A compound of formula
or a tautomer, stereoisomer, or pharmaceutically acceptable salt thereof, wherein
R is —(CR a R b )—O—R 2 ;
R a is H or alkyl;
R b is H or alkyl; or R a and R b together with the atom to which they are attached form a 3 to 8 membered saturated or partially saturated hydrocarbon ring or form a 4 to 8 membered saturated or partially saturated heterocylic ring comprising a ring member selected from O, N(R 3 ) and S;
R 2 is H, alkyl, cycloalkyl or heterocycloalkyl, wherein the alkyl or cycloalkyl may optionally be substituted with halo, alkoxy or heterocycloalkyl; and
R 3 is H or alkyl;
wherein:
heteroaryl is a 5 or 6 membered aromatic ring, comprising one or two ring members selected from N, N(R 4 ), S and O;
alkyl (or the alkyl group of the alkoxy group) is a linear or branched saturated hydrocarbon containing up to 10 carbon atoms;
heterocycloalkyl is a Clinked or N-linked 3 to 10 membered non-aromatic, monocyclic ring, wherein the heterocycloalkyl ring comprises 1, 2 or 3 ring members independently selected from N, N(R 4 ), S(O) q and O;
R 4 is H or alkyl; and
q is 0, 1 or 2.
2. The compound of claim 1 , wherein
R a and R b are independently H; and
R 2 is tetrahydrofuranyl.
3. The compound of claim 1 , wherein R a and R b are independently H.
4. The compound of claim 1 , wherein R is